Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

20 November 2024

Japanese companies struggle due to limited geographical reach

A recent article by pharmaceutical-focused media outlet Yakuji Nippo covers the Access to Medicine Foundation's recently released report, which evaluates large pharmaceutical companies on their efforts to expand access in low- and middle-income countries (LMICs). The article focuses specifically on the Foundation’s analyses of the four Japanese companies included in the analysis.

Direct links

Read the full article

The outlet spoke with Camille Romero, the Foundation’s Research Programme Manager and Marjin Verhoef, Director of Operations and Government Relations, about the results of the 2024 Access to Medicine Index, with the conversation focusing the results related to the four Japanese companies included: Takeda, Eisei, Astellas and Daiichi Sankyo.

It highlights that of the four Japanese companies, Takeda ranked the highest at number nine, due to its integrated drug access strategy and market plan for target countries in its clinical pipeline. However, the three other companies ranked in the last five slots, underlining the need for improvement by these companies in their access-to-medicine efforts in LMICs.

The article also relays the key recommendations for pharmaceutical companies from the report, including increased efforts by pharmaceutical companies in expanding geographic presence of clinical trials, improvements in licensing and engaging in technology transfers.

Read now

2024 Access to Medicine Index

Read more

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Media

Read more about our coverage in global media
Media

Op-ed: How equitable access to medicines can drive sustainable returns for investors

19 November 2024
Media

Global drugmakers fall behind in efforts to make medicines available in poorer countries

19 November 2024
Media

Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

19 November 2024

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved